About Malecare

Malecare is the world's leading men's cancer support and advocacy nonprofit organization.

Light the White House in Blue Lights

Dear President Obama, Prostate cancer will hit one in every six American men. This means that one in every six families will also be affected by prostate cancer. Prostate cancer is the second biggest cancer killer of American men. Sadly, many people don’t know that prostate cancer kills so many men. Prostate cancer is a [...]

Shine a Blue Light on the White House

Shine a light on Prostate Cancer.  Shine a Blue Light.  Shine a Blue Light on our country's leading symbol of democracy, The White House.  An idea from Dan Zenka, the PCF''s V.P. of P.R.. Dan is also a 52 year old newly diagnosed prostate cancer survivor.  Please send your own email to  www.whitehouse.gov/contact, simply asking, [...]

By |2020-02-04T11:52:24-05:00May 7th, 2010|Activism|3 Comments

On The Horizon – PROSTVAC™, The Next Break Out-Prostate Cancer Vaccine To Watch

Bavarian Nordic (B/N) is in the process of testing what might be the next prostate cancer vaccine to become available. They have successfully completed a phase II trial of 125 men with metastatic prostate cancer. The good news, the survival advantage experienced by the trial’s subjects had a statistically significantly longer median overall survival of [...]

US FDA Reviewing the Safety of LHRH Agonists – ADT with Advanced Prostate Cancer

Hormone therapy (ADT), using luteinizing hormone releasing hormone (LHRH) agonists or gonadatropin releasing hormone or GnRH agonists (Lupron, Zoladex, Trelstar, Viadur, Vantas, Eligard and Synarel ) have been known to have many side effects, some severe and potentially life threatening. Many of us believe that ADT is associated with cardiovascular disease and diabetes along with [...]

Analyzing Prostate Cancer Using the CTC-Chip – Insights into the Prognosis of Recurrent Prostate Cancer

Using a CTC-chip that measures the level of circulating tumor cells in blood can provide an important insight into the prognosis and potential rates of recurrent disease, according to data from a developing study at Massachusetts General Hospital, which was presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010. [...]

Go to Top